EP1140940A1 - Derives de 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one utilises en tant qu'agonistes de 5ht2c - Google Patents

Derives de 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one utilises en tant qu'agonistes de 5ht2c

Info

Publication number
EP1140940A1
EP1140940A1 EP99965285A EP99965285A EP1140940A1 EP 1140940 A1 EP1140940 A1 EP 1140940A1 EP 99965285 A EP99965285 A EP 99965285A EP 99965285 A EP99965285 A EP 99965285A EP 1140940 A1 EP1140940 A1 EP 1140940A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
alkyl
hydrogen
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99965285A
Other languages
German (de)
English (en)
Inventor
Annmarie Louise Sabb
Gregory Scott Welmaker
James Albert Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1140940A1 publication Critical patent/EP1140940A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to derivatives of 2,3,4,4a-tetrahydro-lH- pyrazino[l,2,-a]quinoxalin-5(6H)ones which are serotonin 5-hydroxytryptamine 2 C
  • (5HT 2C ) receptor agonists useful for the treatment of disorders such as obsessive - compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders,
  • Obesity is a medical disorder characterized by an excess of body fat or adipose tissue.
  • Comorbidities associated with obesity are Type II diabetes, cardiovascular disease, hypertension, hyperlipidemia, stroke, osteoarthritis, sleep
  • the serotonin 5- hydroxytryptamine (5-HT) receptor is a G-protein coupled receptor which is expressed in neurons in many regions of the human central nervous system.
  • the 5HT, c receptor (formerly called the 5HT 1C receptor) is a prominent subtype of the serotonin receptor found in the central nervous system of both rats and humans. It is expressed widely in both cortical and subcortical regions. [Julius, D. MacDermott, A.
  • 5HT 2r receptor subtype selective agonists which are selective over other monoamine receptors, causes a reduction in food intake and result in a reduction in weight gain.
  • Other therapeutic indications for 5HT 2 c agonists are obsessive compulsive disorder, depression, panic disorder, schizophrenia, sleep disorders, eating disorders, and epilepsy.
  • Indian J. Chem. 17B, 244-245 (1979) discloses 3-Substituted 2,3,4,4a,5,6- Hexahydro-l(H)-pyrazino[l,2-a]quinoxalines which exhibit no anorexigenic or stimulant activity at 60 mg/kg i.p. dose. Weak CNS depressant activity and significant hypotensive activity in anaesthetized animals. Tachyphylaxis was observed.
  • R is hydrogen or alkyl of 1-6 carbon atoms
  • R' is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl
  • R ] , R 2 , R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trilluoroalkyl, -CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of
  • 1-6 carbon atoms dialkylamino of 1-6 carbon atoms per alkyl moiety, trifiuoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
  • X is CR 5 R 6 or a carbonyl group
  • R 5 and R 6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R j ,
  • R 2 , R 3 , or R 4 are not hydrogen; which are 5HT 2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, panic disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.
  • the compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers, enantiomers and diastereoisomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereoisomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.
  • alkyl includes both straight- and branched-chain saturated aliphatic hydrocarbon groups. Preferred alkyl groups are methyl, ethyl, propyl or butyl, most preferably methyl.
  • aroyl is defined as an aryl ether, where aryl is defined as an aromatic system of 6-14 carbon atoms, which may be a single ring or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system.
  • Preferred aryl groups include phenyl, naphthyl, biphenyl, anthryl, tetrahydronaphthyl, phenanthryl groups.
  • Halogen is defined as Cl, Br, F, and I, preferably chlorine or fluorine.
  • Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids.
  • organic and inorganic acids for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable
  • Preferred compounds of this invention are those in which at least one of Ri , R , R 3 , or R 4 are not hydrogen, and the non-hydrogen substituents of R1, R , R 3 , and R 4 are halogen or trifluoromethyl.
  • Preferred enantiomerically pure compounds of formulas IA and IB are provided as follows:
  • R, Rj, R , R 3 , and R 4 are as described above.
  • the compounds of this invention can be prepared according to the following schemes from commercially available starting materials or starting materials which can be prepared using literature procedures. These schemes show the preparation of representative compounds of this invention.
  • the intermediate (III) is cyclized by a process involving reduction of the nitro group to an amino group, preferably by reaction of a metal, such as iron, in an acid, such as acetic acid, followed by heating at elevated temperature, such as 50- 100°C, to effect cyclization to (IV).
  • a metal such as iron
  • an acid such as acetic acid
  • elevated temperature such as 50- 100°C
  • a base such as sodium hydride
  • an alkyl halide such as methyl iodide
  • Compounds (VI) can also be alkylated a second time using a base, such as sodium hydride, and an alkyl halide, such as methyl iodide, to give compounds of this invention (VIII).
  • a base such as sodium hydride
  • an alkyl halide such as methyl iodide
  • compounds (VI) can be reduced with a reducing agent, such as borane in THF, to compounds of this invention (VII).
  • Compounds (VIII) can also be reduced with borane in THF to give (IX) which are compounds of this invention.
  • the amide of compounds (V) can also be reduced to amines (VII) using a reducing agent, such as borane in tetrahydrofuran, at 0-50°C.
  • a reducing agent such as borane in tetrahydrofuran, at 0-50°C.
  • Compounds (VII) are also compounds of this invention.
  • the amide of compounds (VI) can be reduced to amines (VIII) which are compounds of this invention.
  • amines (VIII) which are compounds of this invention.
  • R' is acyl this group is put on, as already described, after reduction of amides (VI) where R' is hydrogen.
  • the enantiomerically pure compounds of this invention can be prepared according to the following Scheme 3 from commercially available starting materials or starting materials which can be prepared using literature procedures.
  • This scheme shows the preparation of representative (R)-compounds of formula IA of this invention, starting with the known 2-(R)-piperazinecarboxylic acid (reference below).
  • Starting from the known 2-(S)-piperazinecarboxylic acid gives the (S)-compounds of formula IB of this invention.
  • the reaction is carried out in an inert organic solvent, such as dimethylformamide, in the presence of a base, such as triethylamine, at a temperature above ambient temperature, such as 50-70°C.
  • a base such as triethylamine
  • the intermediate (XVIII) is cyclized by a process involving reduction of the nitro group to an amino group, preferably by reaction of a metal, such as iron, in an acid, such as acetic acid, followed by heating at elevated temperature, such as 50- 70°C, to effect cyclization to (XIX). Removal of the Cbz protecting group using 30% HBr in acetic acid, boron tribromide, or catalytic reduction, gives chiral products of this invention (IA).
  • Ovary cell line transfected with the cDNA expressing the human 5-hydroxy- tryptamine 2 c (h5HT 2C ) receptor was maintained in DMEM (Dulbecco's Modified Eagle Media) supplied with fetal calf serum, glutamine, and the markers: guaninephosphoribosyl transf erase (GTP) and hypoxanthinethymidine (HT).
  • DMEM Dulbecco's Modified Eagle Media
  • GTP guaninephosphoribosyl transf erase
  • HT hypoxanthinethymidine
  • the cells were allowed to grow to confluence in large culture dishes with intermediate changes of media and splitting. Upon reaching confluence, the cells were harvested by scraping. The harvested cells were suspended in half volume of fresh physiological phosphate buffered saline (PBS) solution and centrifuged at low speed (900 x g). This operation was repeated once more.
  • PBS physiological phosphate buffered saline
  • the collected cells were then homogenized with a polytron at setting #7 for 15 sec in ten volumes of 50 mM Tris.HCl, pH 7.4 and 0.5 mM EDTA.
  • the homogenate was centrifuged at 900 x g for 15 min to remove nuclear particles and other cell debris. The pellet was discarded and the supernatant fluid recentrifuged at 40,000 x g for 30 min. The resulting pellet was resuspended in a small volume of Tris.HCl buffer and the tissue protein content was determined in aliquots of 10-25 microliter ( ⁇ l) volumes.
  • Bovine Serum Albumin (BSA) was used as the standard in the protein determination by the method of Lowry et al., (J. Biol.
  • the volume of the suspended cell membranes was adjusted with 50 mM Tris.HCl buffer containing: 0.1% ascorbic acid, 10 mM pargyline and 4 mM CaCl, to give a tissue protein concentration of 1-2 mg per ml of suspension.
  • the preparation membrane suspension (many times concentrated) was aliquoted in 1 ml volumes and stored at -70°C until used in subsequent binding experiments.
  • Binding measurements were performed in a 96 well microtiter plate format, in a total volume of 200 ⁇ l. To each well was added: 60 ⁇ l of incubation buffer made in 50 mM Tris.HCl buffer, pH 7.4 and containing 4 mM CaCl,: 20 ⁇ l of [ 125 I] DOI (S.A., 2200 Ci/mmol, NEN Life Science).
  • the dissociation constant, KD of [ 125 I] DOI at the human serotonin 5HT C receptor was 0.4 nM by saturation binding with increasing concentrations of [ 125 I] DOI.
  • the reaction was initiated by the final addition of 100.0 ⁇ l of tissue suspension containing 50 ⁇ g of receptor protein. Nonspecific binding is measured in the presence of 1 ⁇ M unlabeled DOI added in 20.0 ⁇ l volume. Test compounds were added in 20.0 ml. The mixture was incubated at room temperature for 60 min. The incubation was stopped by rapid filtration. The bound ligand-receptor complex was filtered off on a 96 well unifilter with a Packard ® Filtermate 196 Harvester.
  • the bound complex caught on the filter disk was dried in a vacuum oven heated to 60°C and the radioactivity measured by liquid scintillation with 40 ⁇ l Microscint-20 scintillant in a Packard TopCount® equipped with six (6) photomultiplier detectors.
  • Ketanserin 94.8 (70.7 - 127.0) nM
  • Methiothepin 4.6 (4.0 - 6.0) nM Methysergide 6.3 (4.6 - 8.6) nM
  • CHO cells transfected with the cDNA expressing the human 5-HT, c receptor were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and non-essential amino acids. Upon reaching confluence the cells were harvested using PBS/EDTA and plated in 24 well plates at an initial density of 2.5 x 10 5 cells per well. One (1) ml of maintenance medium containing l ⁇ Ci ml myo-[ 3 H] inositol was added to each well.
  • DMEM Dulbecco's modified Eagle's medium
  • the cells were washed once with 0.5 ml DMEM containing 25 mM HEPES and 10 mM LiCl, then preincubated with the medium for 30 min (antagonists were included in this period if tested). At the end of the preincubation, the medium was removed, the cells were then incubated with test compounds (in presence of antagonists if needed) for 30 min. The reaction was terminated by removal of the incubation solution and addition of 0.5 ml ice-cold 5% PCA, followed by 15 to 30 min incubation on ice. 200 ⁇ l of 0.5 M Tes/1.5 M K,CO 3 was added to each well to neutralize to pH 7, and plates were left on ice for another 15 to 30 min to precipitate all salts. The liquid and solid phases were separated by centrifugation.
  • a portion (350 ⁇ l) of the upper aqueous phase was applied to Dowex AG-1X8 (formate form, 100-200 mesh) columns. The columns were then washed stepwise with 10 ml of water and 10 ml of 25 mM ammonium formate to remove free myo- [TTJinositol and deacylated phosphoinositol, respectively. Finally 10 ml of 0.2 M ammonium formate solution was applied to the columns to elute [ 3 H] inositol monophosphate ([ 3 H] IP,) directly into scintillation vials. Of this eluate, 1 ml was used to determine radioactivity by scintillation counting.
  • IP [ 3 H]inositol monophosphate
  • ED50 values were calculated. The ED50 value is the dose that produces a 50% reduction in food intake during the test period.
  • the compounds of this invention are 5HT 2C receptor agonists useful for the treatment of diseases involving the central nervous system such as obsessive- compulsive disorder; depression; anxiety; panic disorder; schizophrenia; migraine; sleep disorders, such as sleep apnea; eating disorders, such as hyperphagia; obesity; type II diabetes; and epilepsy.
  • the compounds are for treatment of diseases of a mammal, preferably a human.
  • the compounds of this invention can be formulated neat or with a pharmaceutical carrier for administration, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmacological practice.
  • the pharmaceutical carrier may be solid or liquid.
  • a solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
  • the active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, lecithins, and oils (e.g. fractionated coconut oil and arachis oil).
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration.
  • the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously.
  • the compounds of this invention can also be administered orally either in liquid or solid composition form.
  • the compounds of this invention may be administered rectally or vaginally in the form of a conventional suppository.
  • the compounds of this invention may be formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol.
  • the compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin.
  • the carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
  • the creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type.
  • Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable.
  • a variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.
  • the dosage requirements vary with the particular compositions employed, the route of administration, the severity of the symptoms presented and the particular subject being treated.
  • the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
  • the unit dosage forms can be packaged compositions, for example, packaged powders, vials, ampoules, pre filled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • a mixture of 10.4 g of 4-carbobenzyloxypiperazine-2-carboxylic acid, copper chelate and 7.9 g of ethylenediaminetetraacetic acid, disodium salt in 800 mL of H 2 O is heated to 80°C for 3 hours. After cooling to room temperature, the mixture is concentrated to dryness.
  • a mixture of this solid, 7.3 g of l,2-dichloro-4-fluoro-5- nitrobenzene, and 20 mL of triethylamine in 100 mL of dimethylsulfoxide is heated to 60°C for 12 hours. After cooling to ambient temperature, the resulting mixture is treated with HCl to pH 3. The mixture is then diluted with H,O and extracted with ethyl acetate. The combined extracts are dried over MgSO 4 and concentrated to give 16 g of crude product.
  • a solution of 20 g of KOH in 50 mL of H,O is added to a solution of 4.2 g of 3-carbobenzyloxy-8,9-dichloro-2,3,4,4a-tetrahydro-lH-pyrazino[l,2-a]quinoxalin- 5(6H)-one in 50 mL of methanol.
  • the resulting reaction mixture is heated to reflux for 3 hours and then is allowed to cool to ambient temperature.
  • the solution is concentrated and the crude solid is partitioned between water and ethyl acetate. The phases are separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are concentrated.
  • the crude solid is dissolved in a minimum amount of hot ethanol and then a solution of HCl in ethanol is added to pH 3.
  • the solid is collected and dried in a vacuum oven at 80°C to give 2.4 g of product as its hydrochloride salt.
  • Example 2 (R)-8.9-Dichloro-2.3.4.4a-Tetrahvdro-lH-Pyrazino ⁇ .2-alOuinoxalin-5(6H)-One Method A (Separation Method)
  • the enantiomers of the compound of Example 1 were separated by HPLC using a Chiracel AD column with 100% ethanol at a flow rate of 0.5 mL/min to provide the compounds of Example 2 and 3.
  • the first enantiomer (Example 2) elutes at 10.4 min ([ ⁇ ] 25 D +27.8) and the second (Example 3) at 13.7 min ([ ⁇ ] 25 D -25.5).
  • Method B (Chiral Synthesis)
  • Example 2 The enantiomers of the compound of Example 1 were separated by HPLC using a Chiracel AD column with 100% ethanol at a flow rate of 0.5 mL/min to provide the compounds of Example 2 and 3.
  • the first enantiomer (Example 2) elutes at 10.4 min ([ ⁇ ] 25 D +27.8) and the second (Example 3) at 13.7 min ([ ⁇ ] 25 D -25.5).
  • Method B (Chiral Synthesis)
  • the solids are slurried in 100 mL of 1:1 methanol : water mixture and the pH adjusted to ⁇ 4 by the addition of 2.5 N HCl.
  • the solution is applied to a column of 400 g of AG 50W-8X resin that had been pre- washed with a mixture of 1 :16:16 pyridine : methanol : water.
  • the product was eluted with the same solvent mixture and the combined product fractions are concentrated under reduced pressure ( ⁇ 50°C) to give a semi-solid residue.
  • This material is slurried with 50 mL of methanol to obtain crystalline solids.
  • the solids are collected and dried to give 4.0 g (50%) of white solid, mp 247°C decomposed.
  • This oil is dissolved in 100 mL of ethyl acetate and washed with 20 mL of 1 N HCl (2X), with 100 mL of water (2X), and 100 mL of brine. The organic layer is dried over MgSO 4 , filtered and concentrated to give 2.5 g (99%) an orange solid foam.
  • the enantiomers were be separated by HPLC using a Chirapak AD column with
  • Example 8 85:15 methano water (+0.1% diethylamine) at a flow rate of 0.5 mL/min.
  • the first enantiomer (Example 9) eluted at 17.5 min ([ ⁇ ] 25 D + 43) and the second (Example 8) at 22.0 min ([ ⁇ f D -40).
  • Example 8
  • the enantiomers were separated by HPLC using a Chirapak AD column with 85:15 methanol.'water (+0.1% diethylamine) at a flow rate of 0.5 mL/min.
  • the first enantiomer (Example 9) eluted at 17.5 min ([ ⁇ ] 25 D + 43) and the second (Example 8) at 22.0 min ([ ⁇ ] 25 D -40).
  • the hydrochloride salt was prepared from HCl and MeOH as a light green solid, mp decomposed 270-280°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de la formule (I) et des énantiomères desdits composés, qui s'utilisent comme agonistes du récepteur 5HT2C utiles pour le traitement de troubles affectant le système nerveux central, tels que le trouble obsessionnel-compulsif, la dépression, l'anxiété, la schizophrénie, la migraine, les troubles du sommeil, les troubles de l'alimentation, l'obésité, le diabète de type II, ou l'épilepsie. Dans ladite formule (I), R est hydrogène ou un alkyle de 1 à 6 atomes de carbone; R' est hydrogène, un alkyle de 1 à 6 atomes de carbone, un acyle de 2 à 7 atomes de carbone, ou aroyle; R1, R2, R3 et R4 sont chacun, indépendamment, hydrogène, un alkyle de 1 à 6 atomes de carbone, un alcoxy de 1 à 6 atomes de carbone, halogène, trifluoroalkyle,CN, un alkylsulfonamide de 1 à 6 atomes de carbone, un alkylamide de 1 à 6 atomes de carbone, amino, un alkylamino de 1 à 6 atomes de carbone, un dialkylamino de 1 à 6 atomes de carbone par fraction d'alkyle, un trifluoroalcoxy de 1 à 6 atomes de carbone, un acyle de 2 à 7 atomes de carbone, ou aroyle; X est CR5R6 ou un groupe carbonyle; R5 et R6 sont chacun, indépendamment, hydrogène ou un alkyle de 1 à 6 atomes de carbone; ou leur sel pharmaceutiquement acceptable, à condition qu'au moins R1 ou R2 ou R3 ou R4 ne soit pas hydrogène.
EP99965285A 1998-12-17 1999-12-16 Derives de 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one utilises en tant qu'agonistes de 5ht2c Withdrawn EP1140940A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21347198A 1998-12-17 1998-12-17
US213471 1998-12-17
PCT/US1999/029894 WO2000035922A1 (fr) 1998-12-17 1999-12-16 Derives de 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one utilises en tant qu'agonistes de 5ht2c

Publications (1)

Publication Number Publication Date
EP1140940A1 true EP1140940A1 (fr) 2001-10-10

Family

ID=22795247

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99965285A Withdrawn EP1140940A1 (fr) 1998-12-17 1999-12-16 Derives de 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one utilises en tant qu'agonistes de 5ht2c

Country Status (18)

Country Link
EP (1) EP1140940A1 (fr)
JP (1) JP2002532504A (fr)
KR (1) KR20010108025A (fr)
CN (1) CN1240701C (fr)
AR (1) AR022687A1 (fr)
AU (1) AU3123400A (fr)
BR (1) BR9916326A (fr)
CA (1) CA2351385A1 (fr)
CZ (1) CZ20012193A3 (fr)
EA (1) EA200100671A1 (fr)
HU (1) HUP0104773A3 (fr)
IL (1) IL143323A0 (fr)
NO (1) NO20013001L (fr)
NZ (1) NZ512765A (fr)
PL (1) PL348815A1 (fr)
SK (1) SK8192001A3 (fr)
WO (1) WO2000035922A1 (fr)
ZA (1) ZA200104598B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU2001283955B2 (en) 2000-07-31 2006-05-18 F. Hoffmann-La Roche Ag Piperazine derivatives
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031197A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
US6916922B2 (en) 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR031196A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
EP1330457B1 (fr) * 2000-11-03 2004-10-20 Wyeth Cyclopenta [b][1,4]diazepino 6,7,1-hi]indoles comme antagonistes de 5ht2c
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
CN1227237C (zh) 2000-11-20 2005-11-16 比奥维特罗姆股份公司 作为五羟色胺5－ht2受体拮抗剂的哌嗪基吡嗪化合物
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
HUP0303513A3 (en) 2000-12-20 2005-12-28 Bristol Myers Squibb Pharma Co Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
MXPA03005915A (es) * 2000-12-27 2003-09-10 Hoffmann La Roche Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
CN1512879A (zh) 2001-06-01 2004-07-14 �Ƹ��� 新的芳氨基丙烷类似物及其用于治疗青光眼的用途
WO2002098860A1 (fr) 2001-06-01 2002-12-12 Alcon, Inc. Indazoles et indoles nouveaux fusionnes et leur utilisation dans le traitement de glaucomes
MXPA03010807A (es) 2001-06-01 2004-11-22 Alcon Inc Piranoidazoles y su uso para el tratamiento del glaucoma.
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
MXPA05006277A (es) 2002-12-13 2005-09-08 Alcon Inc Analogos de benzopirano novedosos y su uso para el tratamiento de glaucoma.
AU2003303210A1 (en) 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
CA2529750A1 (fr) * 2003-06-20 2005-02-24 Arena Pharmaceuticals, Inc. Derives de n-phenyl-piperazine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5ht<sb>2c</sb>
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
EP1792629A4 (fr) 2004-08-25 2010-08-25 Takeda Pharmaceutical Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci
WO2006037481A1 (fr) * 2004-09-30 2006-04-13 F.Hoffmann-La Roche Ag Derives de benzoxazine et de quinoxaline et leurs utilisations
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP2018863B9 (fr) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné et utilisation
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
KR101110199B1 (ko) 2009-05-18 2012-03-14 한국화학연구원 피페라진-퀴놀린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
JP5810099B2 (ja) 2010-02-04 2015-11-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ ５−ｈｔ（２ｂ）受容体でアンタゴニスト活性を有する高選択性５−ｈｔ（２ｃ）受容体アゴニスト
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US9067949B2 (en) 2011-01-19 2015-06-30 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
ES2889876T3 (es) 2015-01-29 2022-01-14 Univ Illinois Ciclopropilmetanaminas como agonistas selectivos del receptor 5-HT(2C)
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
US4089958A (en) * 1976-12-20 1978-05-16 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2]quinoxalin-5(6)-ones and derivatives thereof
US4203987A (en) * 1979-05-21 1980-05-20 American Home Products Corporation 3-[Pyridinylalkyl and piperidinylalkyl]-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-ones
GB8917333D0 (en) * 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
EP0539209A1 (fr) * 1991-10-24 1993-04-28 The Upjohn Company Dérivés de benzo-isoquinoléine et analogues et leur utilisation en thérapeutique
WO1996023789A1 (fr) * 1995-02-03 1996-08-08 Sankyo Company, Limited Derives d'hexahydropyrazinoquinoline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0035922A1 *

Also Published As

Publication number Publication date
CN1330652A (zh) 2002-01-09
HUP0104773A2 (hu) 2002-04-29
EA200100671A1 (ru) 2001-12-24
AR022687A1 (es) 2002-09-04
ZA200104598B (en) 2002-09-05
KR20010108025A (ko) 2001-12-07
SK8192001A3 (en) 2001-12-03
WO2000035922A1 (fr) 2000-06-22
PL348815A1 (en) 2002-06-17
CZ20012193A3 (cs) 2001-12-12
NZ512765A (en) 2003-10-31
NO20013001D0 (no) 2001-06-15
BR9916326A (pt) 2001-10-02
NO20013001L (no) 2001-06-15
IL143323A0 (en) 2002-04-21
JP2002532504A (ja) 2002-10-02
AU3123400A (en) 2000-07-03
CN1240701C (zh) 2006-02-08
CA2351385A1 (fr) 2000-06-22
HUP0104773A3 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2000035922A1 (fr) Derives de 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one utilises en tant qu&#39;agonistes de 5ht2c
US7145009B2 (en) Pirazino(aza)indole derivatives
US7271162B2 (en) Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
EP1330457B1 (fr) Cyclopenta [b][1,4]diazepino 6,7,1-hi]indoles comme antagonistes de 5ht2c
WO2002036596A2 (fr) Cycloalkyl[b][1,4]diazepino[6,7,1-hi]indoles et derives
US7271163B2 (en) Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
JP2011505366A (ja) ホスホエステラーゼ１０の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ［１，５−ａ］ピラジン
US20020160997A1 (en) Novel indole derivatives
KR20080063760A (ko) 코르티코트로핀-방출 인자 (ｃｒｆ) 수용체 길항제로서유용한 피라졸로[1,5-알파]피리미디닐 유도체
US6858604B2 (en) Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6503900B2 (en) [1,4]diazepino [6,7,1-jk ]carbazoles and derivatives
WO2003057161A2 (fr) Composes de benzothieno[3,2-c]pyrazolyl et benzofurano[3,2-c]pyrazolyl, leur utilisation lors de maladies associees au recepteur 5-ht2c et leurs composes intermediaires
US6372745B1 (en) 2,3,4,4A-tetrahydro-1H-pyrazino[1,2-A]quinoxalin-5(6H)one derivatives
JPH05505810A (ja) キノキサリン化合物並びにその製造及び使用
US6706714B2 (en) 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
JP2001501949A (ja) 中枢神経系疾患を処置することに有用な５―ヘテロ原子を含有するアルキル置換された―３―オキソ―ピリド（１，２―ａ）ベンゾイミダゾール―４―カルボキサミド誘導体
EA005071B1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ
JP2006525309A (ja) ピロロ（１，２−ｂ）ピリダジン化合物、ならびにＣＲＦ−１受容体拮抗薬としてのその使用
KR20200060404A (ko) 신규한 염
MXPA01005975A (es) Derivados de 2, 3, 4, 4a-tetrahidro-1h-pirazino (1, 2-a) quinoxalin-5 (6h) onas que son agonistas del receptor 2c de 5-hidroxitriptamina (5ht2c)
JP2001512124A (ja) 新規な２，３−ベンゾジアゼピン誘導体
JPH09504789A (ja) ５−ｈｔ１ａレセプターに対して親和性をもつ三環式化合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010606

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010606;LT PAYMENT 20010606;LV PAYMENT 20010606;MK;RO PAYMENT 20010606;SI PAYMENT 20010606

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

17Q First examination report despatched

Effective date: 20030909

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1037620

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090723